Sonar’s New, Powerful Deep-Analysis Capability Finds Hidden Code Level Security Issues
Sonar, the leading Clean Code solution provider, today announced a significant advancement of its Clean Code offering – developers can now automatically discover and fix code security issues arising from interactions between user source code and third-party, open-source libraries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230802497889/en/
Sonar deeper SAST finds hidden code level security issues (Graphic: Business Wire)
Referred to as deeper SAST, the new advanced detection addresses issues that traditional SAST tools miss by not following the flow within library code. Traditional SAST vendors analyze user application code. These tools do not scan the combined code, and flag libraries in an unsophisticated way, ignoring the context and use within the library. The result is that library features are considered black boxes, leaving organizations in the dark about whether they're truly secure for a given context or not. Moreover, these tools typically support only a handful of popular frameworks, often requiring up-front configurations for setup. All of this leads to the security issues created by the unique usage of third-party open source libraries going undetected.
“Code is code, whether it is written by a developer in your team or whether it comes as part of a library that is solving a specific problem. The two different approaches always bothered me, and I am thrilled that we are now able to analyze all codes the same way at once, solving what was considered an impossible problem,” said Olivier Gaudin, CEO and co-founder of Sonar. “With the deeper SAST advancements made to our Clean Code solution, organizations can discover these vulnerabilities and resolve them quickly as code is developed.”
Sonar addresses the gap of traditional SAST through its fine-grained analysis of user source code interactions with external dependencies, all without the need for any special configuration or incremental costs. This deeper SAST innovation furthers Sonar’s mission to equip organizations to achieve a state of Clean Code — code that is consistent, intentional, adaptable, and responsible. When code adheres to these characteristics, software becomes reliable, maintainable, and secure.
“It’s estimated that over 90% of applications leverage third-party libraries and interact with the code within them, but most SAST tools don’t tell developers which dependencies make their code vulnerable. Security is mission-critical, and the more issues you find and fix before they have the ability to cause you harm, the better off your business will be,” said Rik Turner, a Senior Principal Analyst covering cybersecurity at Omdia. “This is the essence of the proactive security wave we are seeing across the cyber sector: find it and fix it before it’s exploited.”
Sonar deeper SAST functionality is available at no additional cost within commercial editions of SonarQube (self-managed) and SonarCloud (cloud-based) — industry-leading static analysis code review tools that continuously inspect and analyze the codebase using quality gates to determine if code meets the defined standards for development and production. Deeper SAST currently supports Java, C#, and TypeScript programming languages and covers thousands of the topmost and commonly used open-source libraries, including their subsequent (transitive) dependencies.
Achieving a Clean Code State
Sonar empowers development teams to write Clean Code by providing them with the right tools and best practices, so they can spend less time fixing issues and more time meeting delivery and business goals. Pairing the Sonar solution with the company’s Clean as You Code methodology — set standards for keeping new, added, or edited code clean — and its educational guidance for code called ‘Learn as You Code,’ developers have faster issue remediation and delivery, code enhancement, and can further professional growth and team retention. Today, there are over seven million developers using Sonar.
Sonar also actively engages with its ecosystem and customer communities, in addition to partnerships with several universities for security research projects, and the open source software and start-up communities. Additionally, Sonar has a dedicated team of security researchers that find and responsibly disclose exploitable zero-day vulnerabilities in open-source software; these findings are used as inspiration for new security rules and detections to help find vulnerabilities.
Learn more about our deeper SAST innovation and Sonar solution (SonarQube, SonarCloud, SonarLint). Meet Sonar experts at Black Hat USA, booth #2760, August 8-10.
About Sonar
Sonar empowers developers and organizations to systematically achieve a state of Clean Code so that all code is fit for development and production. By applying the Sonar Clean as You Code methodology, organizations minimize risk, reduce technical debt, and derive more value from their software in a predictable and sustainable way.
The open source and commercial Sonar solution – SonarLint, SonarCloud, and SonarQube – supports over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering better software.
To learn more about Sonar, please visit https://www.sonarsource.com/company/about/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230802497889/en/
Contact information
Katie Hyman
Senior PR Manager, Sonar
katie.hyman@sonarsource.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
